Cargando…
Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
PURPOSE: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics; however, tools to quantify in situ drug exposure are few. We have...
Autores principales: | Mishra, Akhilesh, Kumar, Dhiraj, Gupta, Kuldeep, Lofland, Gabriela, Sharma, Ajay Kumar, Banka, Dhanush S., Hobbs, Robert F., Dannals, Robert F., Rowe, Steven P., Gabrielson, Edward, Nimmagadda, Sridhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890130/ https://www.ncbi.nlm.nih.gov/pubmed/36449662 http://dx.doi.org/10.1158/1078-0432.CCR-22-1931 |
Ejemplares similares
-
Non-invasive PD-L1 quantification using [(18)F]DK222-PET imaging in cancer immunotherapy
por: Mishra, Akhilesh, et al.
Publicado: (2023) -
Peptide-Based (68)Ga-PET Radiotracer for
Imaging PD-L1 Expression in Cancer
por: De Silva, Ravindra A., et al.
Publicado: (2018) -
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
por: Nimmagadda, Sridhar
Publicado: (2020) -
PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022) -
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
por: Notni, Johannes, et al.
Publicado: (2012)